1. Keeping up with rapid change

   • Jorge Cortes

   Editor’s Commentary Pages: 1 - 1

2. Web alert

   News Pages: 2 - 6

3. Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification

   • Rami S. Komrokji
   • John M. Bennett

   OriginalPaper Pages: 9 - 15

4. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?

   • Mikkael A. Sekeres
   • Alan List

   OriginalPaper Pages: 16 - 19

5. Farnesyltransferase inhibitors in myelodysplastic syndrome

   • E. J. Feldman

   OriginalPaper Pages: 20 - 24

6. New agents in myelodysplastic syndromes

   • Elias Jabbour
   • Francis J. Giles

   OriginalPaper Pages: 25 - 33

7. Arsenic trioxide as a treatment for myelodysplastic syndrome

   • Mikkael A Sekeres

   OriginalPaper Pages: 34 - 38

8. Initial chemotherapy for chronic lymphocytic leukemia: What’s the standard of care?

   • Matt Kalaycio

   Clinical Trials Report Pages: 41 - 42

9. Advances in the treatment of chronic lymphocytic leukemia

   • Nicole Lamanna

   OriginalPaper Pages: 43 - 48

10. First-line treatment of Hodgkin’s lymphoma

    • Beate Klimm
    • Andreas Engert
    • Volker Diehl

    OriginalPaper Pages: 51 - 59

11. Nodular lymphocyte-predominant Hodgkin’s lymphoma

    • Lucia Nogovà
    • Volker Diehl
    • the German Hodgkin Study Group

    OriginalPaper Pages: 60 - 65